Aguracingene cadoparvovec

N/A

Report date: 2023/10/26 16:40:22

Base Information

Drug NameAguracingene cadoparvovec
Drug Alias NamerAAV.hCNGA3AAV8-CNGA3 gene therapy (University Hospital Tubingen)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionCyclic nucleotide-gated cation channel alpha-3 stimulants
TargetsCyclic nucleotide-gated cation channel alpha-3
Therapy Area/IndicationsColor Vision Defects
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEberhard-Karls Universitaet Tuebingen
China Registration ClassN/A

Develop Information

Active CompaniesLudwig Maximilians University Of Munich
Inactive CompaniesN/A
Active IndicationsColor Vision Defects
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A